TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02454452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous vein stripping
Description: Saphenous vein stripping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CHIVA
Description: conservative hemodynamic treatment venous insufficiency
Study: NCT03889990

Intervention type: DEVICE
Group type: OTHER
Intervention: IQOS
Description: Smoke IQOS
Study: NCT01855425

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
Study: NCT01924195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib
Description: Anlotinib QD po.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo QD po.
Study: NCT02422394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Study: NCT02348294

Intervention type: OTHER
Group type: OTHER
Intervention: Shear- force 19 newton and 3,9 kpa pressure for half an hour
Study: NCT01796080

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Steady state normal breathing
Study: NCT01784159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin administration for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin administration for 7 days
Study: NCT01558271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2189265

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02348294

Intervention type: OTHER
Group type: OTHER
Intervention: Shear- force 19 newton and 3,9 kpa pressure for half an hour

Intervention type: OTHER
Group type: OTHER
Intervention: Shear- force 19 newton and 3,9 kpa pressure for half an hour

Intervention type: OTHER
Group type: OTHER
Intervention: Shear- force 19 newton and 3,9 kpa pressure for half an hour
Study: NCT01611922

Intervention type: OTHER
Intervention: Ophthalmic dye
Description: Topically instilled for the purpose of assessing lid margin staining

Intervention type: OTHER
Intervention: Ophthalmic dye
Description: Topically instilled for the purpose of assessing lid margin staining

Intervention type: OTHER
Intervention: Ophthalmic dye
Description: Topically instilled for the purpose of assessing lid margin staining

Intervention type: DEVICE
Intervention: Contact lenses
Description: Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.

Intervention type: DEVICE
Intervention: Contact lenses
Description: Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
Study: NCT03187535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS via ES-130
Description: Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No TEAS
Description: No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
Study: NCT03429582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard C02 Cryotherapy
Description: Standard therapy using carbon dioxide for freezing of tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Tip Thermoablation
Description: Thermoablator outfitted with a 19mm conical tip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiple Tip Thermoablation
Description: Thermoablator outfitted with detachable probes
Study: NCT01301417

Intervention type: DEVICE
Intervention: ColonRing™
Description: Creation of a circular Compression Anastomosis
Study: NCT01407289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart, Insulin Glargine
Description: The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
Study: NCT01558271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Study: NCT01775085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manualized group intervention
Description: MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts \& Sources of Meaning; 2) Identity, Cancer Survivorship, \& Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present \& Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity \& Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, \& Humor; and 8) Transitions: Reflections \& Hopes for the Future.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardized, manualized group intervention
Description: DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
Study: NCT02225925

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Study: NCT00558740

Intervention type: OTHER
Intervention: high protein intake
Description: acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
Study: NCT03925883

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient navigation
Description: Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy
Study: NCT03209596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice (1L/d)
Description: The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control drink (1L/d)
Description: The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
Study: NCT00779285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
Study: NCT02703662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice biologic mesh
Description: Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permacol biologic mesh
Description: Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
Study: NCT01297660

Intervention type: OTHER
Intervention: Video-urodynamic examination
Study: NCT04764903

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study
Study: NCT01116583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)~Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)~Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)~Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4
Study: NCT03681405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Given information about mindful movement and breathing
Study: NCT01957085

Intervention type: OTHER
Intervention: observation only
Description: This is an observational only, nonintervention study. There will be no patient contact. This was a de-identified point prevalence study of hepatitis C infection in hospitalized patients in an inner city hospital.
Study: NCT00407641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin administration
Description: Patients will receive tinzaparin during the HD session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin administration
Description: Patients will receive Heparin as an anticoagulant during the HD session.
Study: NCT03906201

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ecdysterone
Description: Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no pharmacologic effect
Study: NCT01556789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONT-10
Description: ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
Study: NCT05425524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Care Bundle
Description: Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
Study: NCT01821885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry and a brief advice to quit smoking
Description: During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
Study: NCT03681405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01821885

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice to quit smoking
Description: During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
Study: NCT05148689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride Cream, 1%
Description: Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhofade™ (oxymetazoline) cream, 1%
Description: cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cream
Study: NCT04673344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regeneten Collagen Patch
Description: Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
Study: NCT01561040

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3, Vitamins A, D3 and E
Description: omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
Study: NCT01606332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene block with nerve catheter
Description: Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
Study: NCT04282460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin practice
Description: Use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular physical exercise
Description: Take physical exercise for at least half an hour every day in addition to regular physical activities at school.
Study: NCT04418739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
Study: NCT02253992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urelumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT01401985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Capsules
Study: NCT03265288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAU-7b
Description: LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
Study: NCT03125980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine plus oxaliplatin before and after surgery
Description: Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Repeat every 3 weeks (Q3W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine plus oxaliplatin after surgery
Description: Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Q3W
Study: NCT04013984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accupuncture
Description: In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons
Study: NCT01025544

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)
Description: Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix (Haemophilus influenzae type b (Hib) vaccine)
Description: Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
Study: NCT00699062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: singular
Description: The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
Study: NCT03321630

Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib
Description: Lenvatinib 20 mg orally each day on days 1-7

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
Study: NCT03801265

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar plexus block
Description: Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum type 3 block
Description: Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: 0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
Study: NCT00914914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p28
Description: p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
Study: NCT00788749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: tablets 25 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone nasal drops
Description: fluticasone nasal drops 800mcg/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluticasone nasal drops
Description: fluticasone nasal drops 800mcg/d

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone nasal spray
Description: fluticasone nasal spray 400 mcg/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluticasone nasal spray
Description: fluticasone nasal spray 400 mcg/d
Study: NCT00062543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion of CD34+ cells
Description: Donor's cells infused directly into liver through a groin catheter (hepatic artery).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobe Spectra
Description: Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
Study: NCT02737748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWB-103 Group
Description: Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
Study: NCT01561508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-amino-butyric acid
Description: gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Xylitol
Description: The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
Study: NCT04492826

Intervention type: PROCEDURE
Intervention: Postoperative infections rate
Description: Assess the postoperative infection rate after otolaryngology bone flap surgery.